jRCT2031230100Recruiting
Untitled Trial
A Phase 3, Randomized, Double blind, Placebo controlled, Event driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome
(LIBREXIA ACS
)
Janssen Pharmaceutical K.K.Japan Registry Clinical Trial
VerifiedJapan Registry Clinical Trial
Study focus
- Disease/Condition
- Acute Coronary Syndrome
- Study type
- Interventional
Sponsor & location
- Primary sponsor
- Janssen Pharmaceutical K.K.
- Location
- Argentina;Australia; Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Croatia;Czech;Denmark;Estoni
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
ICD-10 classifications
Acute myocardial infarctionAcute myocardial infarction, unspecifiedAcute subendocardial myocardial infarctionAcute ischaemic heart disease, unspecifiedOther acute ischaemic heart diseases
Data source
- Registry
- Japan Registry Clinical Trial
- Trial ID
- jRCT2031230100
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for jRCT2031230100 through Pure Global AI's free database. This phase not specified trial is sponsored by Janssen Pharmaceutical K.K. and is currently Recruiting. The study focuses on Acute Coronary Syndrome.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Japan Registry Clinical Trial data, helping medical device and pharmaceutical companies navigate clinical research efficiently.